Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Beacon Investment Advisory Services Inc.

Beacon Investment Advisory Services Inc. decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 92.3% during the second quarter, Holdings Channel reports. The institutional investor owned 757 shares of the biopharmaceutical company’s stock after selling 9,055 shares during the quarter. Beacon Investment Advisory Services Inc.’s holdings in Regeneron Pharmaceuticals were worth $472,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Palouse Capital Management Inc. lifted its holdings in Regeneron Pharmaceuticals by 6.2% in the second quarter. Palouse Capital Management Inc. now owns 2,479 shares of the biopharmaceutical company’s stock valued at $1,546,000 after acquiring an additional 145 shares during the period. Czech National Bank grew its stake in shares of Regeneron Pharmaceuticals by 3.6% during the 2nd quarter. Czech National Bank now owns 28,442 shares of the biopharmaceutical company’s stock worth $17,735,000 after purchasing an additional 989 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab grew its stake in shares of Regeneron Pharmaceuticals by 17.6% during the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 24,190 shares of the biopharmaceutical company’s stock worth $15,083,000 after purchasing an additional 3,619 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Regeneron Pharmaceuticals by 17.9% during the 2nd quarter. Assenagon Asset Management S.A. now owns 244,927 shares of the biopharmaceutical company’s stock valued at $152,722,000 after purchasing an additional 37,139 shares in the last quarter. Finally, GK Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $210,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Barclays maintained its Buy rating on Regeneron. The reaffirmed bullish view provides support for REGN, particularly after the company’s recent earnings beat, which included revenue growth and earnings per share well above consensus. Barclays Keeps Their Buy Rating on Regeneron
• Neutral Sentiment: Intellia Therapeutics reported lower revenue because of reduced Regeneron collaboration revenue. Intellia’s second-quarter revenue declined 46.2%, but the item reflects Intellia’s financial results rather than a newly announced change in Regeneron’s pipeline or partnership strategy. NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
• Negative Sentiment: Several law firms reiterated notices about a pending securities class action against Regeneron. The lawsuit concerns alleged disclosure issues surrounding the failed Phase 3 melanoma trial, which reportedly led to a substantial market-value loss. Investors who purchased REGN shares during the August 1, 2025–May 15, 2026 class period have until September 14, 2026 to seek lead-plaintiff status. The repeated notices add legal and reputational risk but do not indicate a new lawsuit-related financial liability. Regeneron Class Action Lawsuit Deadline Notice

Regeneron Pharmaceuticals Stock Up 1.6%

REGN stock opened at $784.36 on Friday. The stock has a market capitalization of $82.92 billion, a P/E ratio of 19.39, a P/E/G ratio of 1.34 and a beta of 0.22. The firm has a 50-day simple moving average of $657.28 and a 200-day simple moving average of $712.33. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period last year, the company posted $12.81 EPS. Regeneron Pharmaceuticals’s quarterly revenue was up 16.7% compared to the same quarter last year. Equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.29%.

Analyst Ratings Changes

Several analysts recently commented on the stock. HSBC dropped their price target on shares of Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Truist Financial raised their target price on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Canaccord Genuity Group cut their price target on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Sanford C. Bernstein upgraded Regeneron Pharmaceuticals to a “hold” rating in a research report on Wednesday, July 29th. Finally, Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $797.75.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 200 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.